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Abstract
Malignant fibrous histiocytoma (MFH) is an aggressive spindle cell cancer of soft-tissue sarcoma type in the elderly,
mostly affecting the extremities. Lesions > 5 cm, positive margins, and local recurrence are significant poor
prognostic indicators. The strongest predictor for distant metastasis was tumor size (> 5 cm), and for overall
survival, presence of local recurrence. Limb-sparing extensive tumor resection is preferred to achieve negative
surgical margins. However, in some circumstances, amputation is inevitable. Recent studies demonstrated that
adjuvant radiotherapy for microscopically positive surgical margins significantly improved local control and disease-
free survival rates. Therefore, effective therapeutic strategies against locally relapsed high grade MFH are required
to prevent distant metastasis and to achieve long-term disease-free survival. Here, we report local relapse of high
grade MFH treated by successive application of autologous formalin-fixed tumor vaccination (AFTV) with limb-
sparing surgery and postoperative radiotherapy. The patient is alive and well, disease-free and with no functional
impairment, more than five years after treatment.
Background
Malignant fibrous histiocytoma (MFH) is the most com-
mon soft-tissue sarcoma. When located in a limb, MFH
is currently treated with limb-sparing surgery followed
by > 65 Gy external beam radiotherapy [1,2]. For
patients with locally recurrent large tumors (> 5 cm in
diameter) on the thigh, limb-sparing surgery with ade-
quate clearance margins is desirable but not always
attainable. Additionally, large tumors often result in dis-
tant metastasis [1], for which there is currently no effec-
tive chemotherapy [2]. Patients thus face amputation for
complete tumor removal; so improved treatment options
are urgently required for locally recurrent high-grade
MFH. Here, we report application of autologous forma-
lin-fixed tumor vaccination (AFTV) combined with
limb-sparing surgery and followed by anticipatory 74 Gy
external electron beam radiotherapy in an elderly dia-
betic patient with locally recurrent MFH after primary
limb-sparing surgery. The vaccine was prepared from
both the recurrent and the primary tumor after limb-
sparing surgery [3].
Case report
A 72-year old man presented with a painful ulcerative
tumor (4.5 cm) at the location of a scar on the right
thigh, where a mass 7.5 cm in diameter had been
resected at a different clinic three months earlier. No
pathological information was available at the time, but
because of the painful infected lesion, we promptly
removed the tumor, which had cloudy exudates at the
ulcerative surface. The patient had suffered > 5 years
from poorly controlled diabetes mellitus (DM) with
blood sugar at 272 mg/dl and an elevated HbA1C of
9.4%, but no ketone bodies in the urine. Other labora-
tory tests revealed signs of slight inflammation, includ-
ing a WBC of 6,540/mm
3 and a CRP of 0.35 mg/dl. We
removed the tumor with 1.5 cm horizontal margins, pre-
serving the fascia lata. DM was treated orally. Pathologi-
cal examination revealed that the mass was a malignant
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liferating fibroblastic and histiocytic tumor cells with
bizarre nuclei, abundant mitotic activity, a pleomorphic
pattern and necrotic areas. These findings were identical
in the primary extirpated tumor (7.5 cm) reported in
the meantime by the previous clinic (Figure 1). This cor-
responds to the UICC classification of high grade (G3-
deep) MFH, stage III [4]. Because pathology showed
that the vertical surgical margin was positive, magnetic
resonance imaging (MRI) and positron emission com-
puted tomography (PET-CT) was undertaken 5 weeks
after surgery. This revealed small mass at the vertical
surgical margin, but no metastatic lesions (Figure 2).
Beginning 6 weeks after the second tumor removal, elec-
tron beam adjuvant radiotherapy using a shrinking field
technique was used to deliver a total dose of 74 Gy in
fractions of 2.0 Gy over 5 consecutive days per week
(Figure 3). Initial 6 MV X-ray was irradiated by using
lateral opposed field with 15-degree wedge filter and 5
mm bolus to surgical scar and tumor bed up to 50 Gy/
25 fractions/5 weeks. After that, 24 Gy/12 fractions/2.4
weeks of irradiation was delivered to surgical scar with
6 MeV electron beam as a boost. Paraffin-embedded
primary tumor and the formalin-fixed recurrent tumor
were injected intradermally three times every two weeks
as AFTV. Delayed-type hypersensitivity (DTH) testing
both before the first injection and 48 hours later was
negative. DTH two weeks after the final AFTV injection
was judged pseudo-positive (Figure 4). Immune para-
meters after treatment were normalized (Additional File
1). The treatment course was uneventful; there were no
adverse effects. Around 5 years after the primary limb-
sparing surgery the patient remains well with no evi-
dence of metastasis or local recurrence (Figure 5) and
the third DTH test performed around 4 years after
AFTV was apparently positive (Figure 6).
Discussion and conclusions
Combining limb-sparing surgery and postoperative
radiotherapy with > 65 Gy is standard treatment for
patients with high grade large MFH [1]. Treatment of
local recurrence of such tumors would also require
Figure 1 microscopic photograps (HE: X200). Primary (left) and
Recurrent (right) tumors are consisted of proliferative fibroblastoid
cells, bizarre nucleated cells with high mitotic activity and partially
necrotic areas.
Figure 2 MRI & PET-CT.A :M R Ii m a g ed e m o n s t r a t e sas m a l l
recurrent tumor on the vertical surgical margin at the fascia lata of
the right thigh. B: PET-CT mages in coronary (1) and sagittal (2)
sections of the right thigh and hot spots indicate the recurrent
tumor.
Figure 3 Post-operative radiation fields. Post-operative radiation
fields in shrinking field technique.
Figure 4 Autologuos tumor specific delayed type
hypersensitivity test (DTH). White arrow indicates pseudo-positive
reaction.
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However, no effective chemotherapeutic regimen exists.
Here, we applied AFTV from the start of postoperative
radiotherapy instead of chemotherapy, in consideration
of the patient’s uncontrolled DM. Details of the AFTV
have already been reported [5]. We used a mixture of
both paraffin-embedded primary tumor and formalin-
fixed secondary tumor as the vaccine. In this way, we
aimed to include the original tumor antigens in the pri-
mary tumor as well as any possible alterations of the
expressed tumor antigens in the progressive metastatic
tumor cells. The objective was to eradicate the micro-
scopically observed tumor cells remaining after surgery
and irradiation. Hafner et al. reported that decreased
immune surveillance might play a role in the develop-
ment of MFH, based on a significant increase in its
incidence in a large series of renal transplant patients
(156 per 100,000) [6]. This was another reason to
attempt AFTV rather than chemotherapy. Even in the
present time, there is no clinically appropriate estimat-
ing system of antitumor cellular immune reactivity for
the particular patient. Since DTH testing is commonly
used to measure specific antitumor cellular immune
reactivity we used it to evaluate antitumor cellular
immune status in the different timing as just before,
complete, and late after AFTV. The reactivity has
strengthened from pseudo and true positive during 4
years after AFTV in the reported case. Radiation therapy
of 74 Gy by using shrinking field technique has very
efficiently controlled locally relapse high grade MFH. As
conclusion, results for the case reported here suggest
that AFTV in combination with limb-sparing surgery
and adjuvant radiotherapy might extend survival of
patients with locally advanced high grade MFH of extre-
mities with enhancing specific antitumor immune
reactivity.
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Written consent was obtained from the patient for pub-
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Figure 5 Coronary sections of MRI and PET-CT, and
Photograph on the right thigh. No tumor exist 30 months after
treatments on these images.
Figure 6 Positive DTH test. Positive DTH test performed around 4
years after completion of AFTV.
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